Cell Robotics Secures $2 Million Private Financing.Business Editors & Health Industry Writers ALBUQUERQUE, N.M.--(BUSINESS WIRE)--May 30, 2000 Proceeds Will Drive Production, Marketing and Sales of the Personal Lasette(R), Used by Diabetics to Draw Blood for Glucose Testing Cell Robotics International Inc.(OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CRII CRII Cooperative Research in Information Infrastructure CRII Customer Returns Improvement Initiative ), a medical laser device company, today announced that it has successfully secured $2,000,000 in equity financing Equity Financing The act of raising money for company activities by selling common or preferred stock to individual or institutional investors. In return for the money paid, shareholders receive ownership interests in the corporation. through the sale of 500,000 shares (at a price of $4.00 per share) of its unregistered common stock to Paulson Investment Company of Portland, Ore. The company has agreed to file a registration statement for these shares in the near future. This transaction, which was previously announced on May 8, 2000, was contingent upon Adj. 1. contingent upon - determined by conditions or circumstances that follow; "arms sales contingent on the approval of congress" contingent on, dependant on, dependant upon, dependent on, dependent upon, depending on, contingent shareholders authorizing additional common stock at the May 19 annual meeting of shareholders. At that meeting, the shareholders approved an increase in the company's authorized common stock, thus authorizing completion of the transaction. The proceeds from this private placement will be used primarily for the manufacturing, sales and marketing efforts of the company's proprietary, leading-edge laser device, the Personal Lasette(R). The Personal Lasette(R) is the only FDA-cleared, currently available alternative to the needle or steel blade lancet for diabetics to draw blood to test their blood glucose levels blood glucose level, n level of glu-cose in the bloodstream, normally about 70 to 115 mg/dL after fasting overnight. Higher levels may indicate diseases such as diabetes mellitus. . Low blood glucose levels signal the need for the diabetic to have a snack or an insulin injection, pursuant to the particular patient's doctor's orders "Doctor's Orders" is the title of an episode from the third season of the television series . Its episode number is 068, and it first aired on 18 February 2004. Plot summary This is a summary of the beginning portion of the episode. . The Personal Lasette(R) causes little pain, reduces finger soreness and eliminates the fear of sticking a steel lancet into one's finger. Cell Robotics' president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Dr. Ronald Lohrding, commented: "Our business plan is being implemented; with production of the Personal Lasette(R) increasing and this financing in place, we can aggressively expand our marketing and sales from only direct sales to agreements with large first-rate distributors. The development of the distributor network is an additional component in process for proceeding full speed ahead on our plans for marketing and selling this revolutionary product." Dr. Lohrding added, "We hope that when diabetes patients look back at early 2000, they will see this as the time in which the steel lancet gave way to the Personal Lasette(R) as the standard of diabetes care." About Cell Robotics International Cell Robotics International is a medical products company committed to enhancing the quality of life through technology. CRII manufactures, markets and sells the Lasette, the only FDA-cleared alternative to the needle or steel blade lancet currently available for diabetics to draw blood so as to test their glucose levels. The company's additional products include the Cell Robotics Workstation(TM), an innovative scientific research instrument that uses laser light to transform a microscope from a viewing device into a tool for physically manipulating and dissecting dis·sect tr.v. dis·sect·ed, dis·sect·ing, dis·sects 1. To cut apart or separate (tissue), especially for anatomical study. 2. living cells in microspace. Forward-looking statements (statements which are not historical fact) in this release are made pursuant to the safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Investors are cautioned that all forward-looking statements involve risks and uncertainties, including the following: changes in economic conditions, general competitive factors, the company's ability to execute its manufacturing, service and product sales plans and uncertainties detailed in the company's filings with the Securities and Exchange Commission. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion